Prelude Therapeutics Inc (PRLD)

$1.71 +0.08 (4.91%)
Market Cap 107.50M
Revenue (ttm) 7.00M
Net Income (ttm) -127.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,816.71%
Debt to Equity Ratio 0.00
Volume 341,600
Avg Vol 1,646,824
Day's Range N/A - N/A
Shares Out 62.87M
Stochastic %K 98%
Beta 1.06
Analysts Strong Sell
Price Target $4.00

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 467 1280
Address:
175 Innovation Boulevard, Wilmington, United States
Jaybird827
Jaybird827 Dec. 14 at 12:41 PM
$PRLD is their any truth to the lawsuit? Maybe Merck is pulling out due to that. 🤷
0 · Reply
MrEsKurr
MrEsKurr Dec. 13 at 12:20 AM
$PRLD quiet ones are the ones that pay the most lately. Im in!! 1...7...2..
0 · Reply
LabPsycho
LabPsycho Dec. 12 at 4:16 PM
$PRLD @tahloolaaa If it is so standard, then cite another example of a company that invested in shares of another company then a few weeks later have the investment dropped 60% file to sell. @SteelcityTrader44
1 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 11 at 11:44 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $PRLD | Timeframe: 6M / 1D Market Cap: $102.47M • Pattern score: 0.76 • Current price: $1.630 • Peak (window): $3.980 • Trough (post-spike): $1.190 • Pullback: ~70.1% from peak • Move off lows: ~41.0% of peak Stock Plan (educational only) • Entry zone: $1.581 – $1.663 • Scalp target: $1.760 → Est. ROI: ~8.0% • Swing target: $2.608 → Est. ROI: ~60.0% • Protective stop: $1.385 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-03-20 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.475 → Exit target: ~$0.831 (≈+75% vs entry) → Protective stop: ~$0.285 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $GME
0 · Reply
LabPsycho
LabPsycho Dec. 11 at 5:31 PM
$PRLD @SteelcityTrader44 IMO, 1. Maybe the $25MILLION purchase was just fluff to make it seem like PRLD was worth a lot more than it was? 2. Maybe INCY bought shares then later found out PRLD pausing / stopping clinical development? 3. Maybe INCY wants to take a tax loss to offset profits 4. Maybe they've been selling..IMO it seems the trading volume on PRLD is about 2X what is was before the INCY deal. My conclusion Something weird is going on with PRLD and IMO is a completely different company than it was a few months ago.
1 · Reply
vu_jade
vu_jade Dec. 11 at 5:07 PM
$PRLD added
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 11 at 4:53 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $PRLD | Timeframe: 6M / 1D Market Cap: $103.73M • Pattern score: 0.77 • Current price: $1.650 • Peak (window): $3.980 • Trough (post-spike): $1.190 • Pullback: ~70.1% from peak • Move off lows: ~41.5% of peak Stock Plan (educational only) • Entry zone: $1.600 – $1.683 • Scalp target: $1.782 → Est. ROI: ~8.0% • Swing target: $2.640 → Est. ROI: ~60.0% • Protective stop: $1.402 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-03-20 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.475 → Exit target: ~$0.831 (≈+75% vs entry) → Protective stop: ~$0.285 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $EBS
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 11 at 3:05 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $PRLD | Timeframe: 6M / 1D Market Cap: $103.73M • Pattern score: 0.77 • Current price: $1.650 • Peak (window): $3.980 • Trough (post-spike): $1.190 • Pullback: ~70.1% from peak • Move off lows: ~41.5% of peak Stock Plan (educational only) • Entry zone: $1.600 – $1.683 • Scalp target: $1.782 → Est. ROI: ~8.0% • Swing target: $2.640 → Est. ROI: ~60.0% • Protective stop: $1.402 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-03-20 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.475 → Exit target: ~$0.831 (≈+75% vs entry) → Protective stop: ~$0.285 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $META
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 11 at 1:21 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $PRLD | Timeframe: 6M / 1D Market Cap: $103.73M • Pattern score: 0.77 • Current price: $1.650 • Peak (window): $3.980 • Trough (post-spike): $1.190 • Pullback: ~70.1% from peak • Move off lows: ~41.5% of peak Stock Plan (educational only) • Entry zone: $1.600 – $1.683 • Scalp target: $1.782 → Est. ROI: ~8.0% • Swing target: $2.640 → Est. ROI: ~60.0% • Protective stop: $1.402 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-03-20 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.475 → Exit target: ~$0.831 (≈+75% vs entry) → Protective stop: ~$0.285 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $BBAI
0 · Reply
SteelcityTrader44
SteelcityTrader44 Dec. 11 at 1:15 AM
$PRLD S-3 out. 6M shares now registered to sell. The kicker is the seller bought last month for $4. Cant imagine them taking a L this big already… I smell a big pump coming for them to start to sell.
1 · Reply
Latest News on PRLD
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

Dec 6, 2025, 11:00 AM EST - 7 days ago

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Nov 26, 2025, 11:10 AM EST - 17 days ago

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 8:31 PM EST - 4 weeks ago

Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call Transcript

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 7:01 AM EST - 4 weeks ago

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

Nov 11, 2025, 11:24 PM EST - 4 weeks ago

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

Prelude Therapeutics Announces Strategic Business Update

Nov 4, 2025, 7:05 AM EST - 5 weeks ago

Prelude Therapeutics Announces Strategic Business Update

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Nov 4, 2025, 7:01 AM EST - 5 weeks ago

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Nov 3, 2025, 9:01 AM EST - 5 weeks ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Oct 17, 2025, 7:30 AM EDT - 2 months ago

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:00 AM EDT - 4 months ago

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Jun 2, 2025, 7:30 AM EDT - 6 months ago

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 4:05 PM EDT - 7 months ago

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025, 7:30 AM EDT - 8 months ago

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Prelude Announces Presentations at 2025 AACR Annual Meeting

Apr 25, 2025, 4:05 PM EDT - 8 months ago

Prelude Announces Presentations at 2025 AACR Annual Meeting

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Mar 10, 2025, 7:30 AM EDT - 9 months ago

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 7:30 AM EST - 10 months ago

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Dec 11, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Nov 27, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 13, 2024, 10:00 AM EDT - 1 year ago

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 9, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Apr 9, 2024, 4:35 PM EDT - 1 year ago

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 1 year ago

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Feb 29, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Prelude Therapeutics Announces $25 Million Private Placement

Dec 11, 2023, 9:34 AM EST - 2 years ago

Prelude Therapeutics Announces $25 Million Private Placement

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Nov 1, 2023, 4:10 PM EDT - 2 years ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Aug 29, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 31, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 17, 2023, 4:08 PM EDT - 2 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

May 8, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Apr 27, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Feb 9, 2023, 9:05 AM EST - 3 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Nov 14, 2022, 8:00 AM EST - 3 years ago

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

May 10, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Prelude Therapeutics Reports Full Year 2021 Financial Results

Mar 16, 2022, 7:30 AM EDT - 4 years ago

Prelude Therapeutics Reports Full Year 2021 Financial Results

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Mar 11, 2022, 8:00 AM EST - 4 years ago

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Mar 9, 2022, 8:05 AM EST - 4 years ago

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Jaybird827
Jaybird827 Dec. 14 at 12:41 PM
$PRLD is their any truth to the lawsuit? Maybe Merck is pulling out due to that. 🤷
0 · Reply
MrEsKurr
MrEsKurr Dec. 13 at 12:20 AM
$PRLD quiet ones are the ones that pay the most lately. Im in!! 1...7...2..
0 · Reply
LabPsycho
LabPsycho Dec. 12 at 4:16 PM
$PRLD @tahloolaaa If it is so standard, then cite another example of a company that invested in shares of another company then a few weeks later have the investment dropped 60% file to sell. @SteelcityTrader44
1 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 11 at 11:44 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $PRLD | Timeframe: 6M / 1D Market Cap: $102.47M • Pattern score: 0.76 • Current price: $1.630 • Peak (window): $3.980 • Trough (post-spike): $1.190 • Pullback: ~70.1% from peak • Move off lows: ~41.0% of peak Stock Plan (educational only) • Entry zone: $1.581 – $1.663 • Scalp target: $1.760 → Est. ROI: ~8.0% • Swing target: $2.608 → Est. ROI: ~60.0% • Protective stop: $1.385 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-03-20 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.475 → Exit target: ~$0.831 (≈+75% vs entry) → Protective stop: ~$0.285 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $GME
0 · Reply
LabPsycho
LabPsycho Dec. 11 at 5:31 PM
$PRLD @SteelcityTrader44 IMO, 1. Maybe the $25MILLION purchase was just fluff to make it seem like PRLD was worth a lot more than it was? 2. Maybe INCY bought shares then later found out PRLD pausing / stopping clinical development? 3. Maybe INCY wants to take a tax loss to offset profits 4. Maybe they've been selling..IMO it seems the trading volume on PRLD is about 2X what is was before the INCY deal. My conclusion Something weird is going on with PRLD and IMO is a completely different company than it was a few months ago.
1 · Reply
vu_jade
vu_jade Dec. 11 at 5:07 PM
$PRLD added
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 11 at 4:53 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $PRLD | Timeframe: 6M / 1D Market Cap: $103.73M • Pattern score: 0.77 • Current price: $1.650 • Peak (window): $3.980 • Trough (post-spike): $1.190 • Pullback: ~70.1% from peak • Move off lows: ~41.5% of peak Stock Plan (educational only) • Entry zone: $1.600 – $1.683 • Scalp target: $1.782 → Est. ROI: ~8.0% • Swing target: $2.640 → Est. ROI: ~60.0% • Protective stop: $1.402 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-03-20 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.475 → Exit target: ~$0.831 (≈+75% vs entry) → Protective stop: ~$0.285 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $EBS
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 11 at 3:05 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $PRLD | Timeframe: 6M / 1D Market Cap: $103.73M • Pattern score: 0.77 • Current price: $1.650 • Peak (window): $3.980 • Trough (post-spike): $1.190 • Pullback: ~70.1% from peak • Move off lows: ~41.5% of peak Stock Plan (educational only) • Entry zone: $1.600 – $1.683 • Scalp target: $1.782 → Est. ROI: ~8.0% • Swing target: $2.640 → Est. ROI: ~60.0% • Protective stop: $1.402 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-03-20 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.475 → Exit target: ~$0.831 (≈+75% vs entry) → Protective stop: ~$0.285 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $META
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 11 at 1:21 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $PRLD | Timeframe: 6M / 1D Market Cap: $103.73M • Pattern score: 0.77 • Current price: $1.650 • Peak (window): $3.980 • Trough (post-spike): $1.190 • Pullback: ~70.1% from peak • Move off lows: ~41.5% of peak Stock Plan (educational only) • Entry zone: $1.600 – $1.683 • Scalp target: $1.782 → Est. ROI: ~8.0% • Swing target: $2.640 → Est. ROI: ~60.0% • Protective stop: $1.402 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-03-20 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.475 → Exit target: ~$0.831 (≈+75% vs entry) → Protective stop: ~$0.285 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $BBAI
0 · Reply
SteelcityTrader44
SteelcityTrader44 Dec. 11 at 1:15 AM
$PRLD S-3 out. 6M shares now registered to sell. The kicker is the seller bought last month for $4. Cant imagine them taking a L this big already… I smell a big pump coming for them to start to sell.
1 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 10 at 11:28 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $PRLD | Timeframe: 6M / 1D Market Cap: $103.73M • Pattern score: 0.77 • Current price: $1.650 • Peak (window): $3.980 • Trough (post-spike): $1.190 • Pullback: ~70.1% from peak • Move off lows: ~41.5% of peak Stock Plan (educational only) • Entry zone: $1.600 – $1.683 • Scalp target: $1.782 → Est. ROI: ~8.0% • Swing target: $2.640 → Est. ROI: ~60.0% • Protective stop: $1.402 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-03-20 • Example Strike: ~$1.500 (≈5% OTM) • Example Premium (entry): ~$0.475 → Exit target: ~$0.831 (≈+75% vs entry) → Protective stop: ~$0.285 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $UNH
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Dec. 10 at 10:16 PM
$PRLD
1 · Reply
vu_jade
vu_jade Dec. 10 at 8:52 PM
$PRLD long
0 · Reply
Danyola
Danyola Dec. 10 at 3:56 PM
$PRLD Stocks Stuck in Wait-and-See Mode Ahead of Fed: Markets Wrap This content was published on December 10, 2025 - 16:27 (Bloomberg) — Stocks are marking a second day of muted trading as traders wait to hear the Federal Reserve’s views on interest rates for 2026 after an expected cut at Wednesday’s policy meeting. Bitcoin slid.
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 10 at 3:30 PM
🎯 Target Hit 🏁 📨 From Dec 3, 2025 💊 $PRLD 💵 Entry: $1.3800 ✅ Ext: $1.6174 💰 P/L: +17.20% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
allyboy
allyboy Dec. 9 at 9:35 PM
$PRLD wasnt borning today! 16.43%
0 · Reply
Stmkr
Stmkr Dec. 8 at 5:54 AM
$PRLD $INCY Interesting to follow whether PRLD's mCARL-targeted DAC can do better. Already 1 partnership between $INCY and $PRLD https://investor.incyte.com/news-releases/news-release-details/incytes-first-class-mutcalr-targeted-monoclonal-antibody
1 · Reply
CrassVee
CrassVee Dec. 8 at 1:11 AM
Here is a Weekly Watchlist Friends.. *Sorry for the Delay* Big Family weekend. I put my time in here, but I know a few of these are Already on Watch. I Aim to Provide the New Plays/Moves coming on this watchlist. I have others I'm watching as well. But I aim to Trim these lists with a little variety. @BearTamerTrading & I Aim to Provide for the Retail Community from 6am-6pm. Live CallOuts PM & AH. Come See What We are about; Mondays are Free for NewComers; Hope to See You There https://www.youtube.com/live/_1IcrKGCuzQ?si=hhWfZWDo2v2oXBpM https://www.youtube.com/live/3DRdWK7FTzs?si=SBwlAujl4x_nnV9J $KZIA $TWG $TGL $KXIN $PRLD
1 · Reply
AlertsAndNews
AlertsAndNews Dec. 6 at 9:42 PM
$PRLD Another ash headline. Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
0 · Reply
BiotechValues
BiotechValues Dec. 5 at 4:01 PM
$BCAB should know who the partner is within 2 weeks of today. Been chatting with GROK and it seems convinced that EXEL (ChatGTP #1) or INCY (its #1) are the top contenders based on the HPV+ focus (see below). $INCY has been very vocal on doing deals and just did one with $PRLD
1 · Reply
Dizzier47
Dizzier47 Dec. 2 at 9:53 PM
$PRLD the dip before the rip
0 · Reply
MUBSN
MUBSN Dec. 2 at 9:26 PM
$PRLD added 18800 at 4.18 in friday
1 · Reply